Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

Molecular Cancer Therapeutics

Volumn 9, Issue 10, 2010, Pages 2689-2699

  Lopus, Manu ^a   Oroudjev, Emin ^a   Wilson, Leslie ^a   Wilhelm, Sharon ^b   Widdison, Wayne ^b   Chari, Ravi ^b   Jordan, Mary Ann ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MAYTANSINE; N 2' DEACETYL N 2' (3 THIOMETHYL 1 OXOPROPYL)MAYTANSINE; N 2' DEACETYL N 2' (4 THIOMETHYL 4 METHYL 1 OXOPENTYL)MAYTANSINE; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; MICROTUBULE; MICROTUBULE ASSEMBLY; MICROTUBULE DYNAMIC INSTABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; CATTLE; IMMUNOCONJUGATES; MAYTANSINE; MICE; MICROTUBULES; POLYMERS; SOLUBILITY; TUBULIN;

EID: 77958043944     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0644     Document Type: Article

References (38)

1. Kupchan SM, Komoda Y, Branfman AR, et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J Org Chem 1977;42:2349-57.
2. Kupchan SM, Komoda Y, Court WA, et al. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972;94:1354-6.
3. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975;189:1002-5.
4. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG. Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 1976;72:47-54.
5. Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett 1977;75:159-62.
6. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 2004;52:1-26.
7. Annual Report to the FDA by DCT, NCI, on Maytansine, NSC 153858, IND 11857, February 1984.
8. Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 2004;10:4363-8.
9. Smith SV. Technology evaluation: cantuzumab mertansine, Immuno- Gen. Curr Opin Mol Ther 2004;6:666-74.
10. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010;21:84-92.
11. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
12. Krop I, LoRusso P, Miller KD, et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab; San Antonio Breast Cancer Symposium 2009; abstract #710.
13. Lopus M, Yenjerla M, Wilson L. Microtubule dynamics. In: Begley TP, editor. Encyclopedia of chemical biology. 3. New Jersey: John Wiley & Sons; 2009, p. 153-60.
14. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
15. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007;7:730-42.
16. Widdison W, Wilhelm S, Cavanagh E, et al. Semisynthetic maytansine analogs for targeted treatment of cancer. J Med Chem 2006;49:4392-408.
17. Xie H, Audette C, Hoffee M, et al. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-1) and its two components in mice. J Pharm Exp Ther 2004;308:1073-82.
18. Farrell KW, Wilson L. Tubulin-colchicine complexes differentially poison opposite microtubule ends. Biochemistry 1984;23:3741-8.
19. Miller HP, Wilson L. Preparation of microtubule protein and purified tubulin from bovine brain by cycles of assembly and disassembly and phosphocellulose chromatography. Methods Cell Biol 2010;95:3-15.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of proteindye binding. Anal Biochem 1976;72:248-54.
21. Yenjerla M, Lapointe NE, Lopus M, et al. The neuroprotective peptide NAP does not directly affect polymerization or dynamics of reconstituted neural microtubules. J Alzheimers Dis 2010;19:1377-86.
22. Yenjerla M, Lopus M, Wilson L. Analysis of dynamic instability of steady-state microtubules In Vitro by video-enhanced differential interference contrast microscopy. Methods Cell Biol 2010;95:189-202.
23. Walker RA, O'Brien ET, Pryer NK, et al. Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies. J Cell Biol 1998;107:1437-48.
24. Aneja R, Vangapandu SN, Lopus M, Panda D, Chandra R, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006;69:1801-9.
25. Jordan MA, Ojima I, Rosas F, et al. Effects of novel taxanes SBT-1213 and IDN5109 on tubulin polymerization and mitosis. Chem Biol 2002;9:93-101.
26. Rosenthal HE. A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 1967;20:525-32.
27. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7.
28. Wilson L, Jordan MA, Morse A, Margolis RL. Interaction of vinblastine with steady state microtubules in vitro. J Mol Biol 1982;159:125-49.
29. Jordan MA, Walker D, de Arruda M, Barlozzari T, Panda D. Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry 1998;37:17571-8.
30. Panda D, Daijo JE, Jordan MA, Wilson L. Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-colchicine complex. Biochemistry 1995;34:9921-9.
31. Correia JJ. Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther 1991;52:127-47.
32. Lin CM, Hamel E. Effects of inhibitors of tubulin polymerization on GTP hydrolysis. J Biol Chem 1981;256:9242-5.
33. York J, Wolpert-DeFilippes MK, Johns DG, Sethi VS. Binding of maytansinoids to tubulin. Biochem Pharmacol 1981;30:3239-43.
34. Fellous A, Ludueña RF, Prasad V, et al. Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. Cancer Res 1985;45:5004-10.
35. Singer WD, Jordan MA, Wilson L, Himes RH. Binding of vinblastine to stabilized microtubules. Mol Pharmacol 1989;36:366-70.
36. Panda D, Jordan MA, Chu KC, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem 1996;271:29807-12.
37. Roach MC, Ludueña RF. Different effects of tubulin ligands on the intrachain cross-linking of β 1-tubulin. J Biol Chem 1984;259:12063-71.
38. Cormier A, Marchand M, Ravelli RB, Knossow M, Gigant B. Structural insight into the inhibition of tubulin by Vinca domain peptide ligands. EMBO Rep 2008;9:1101-6.